NR-SAFE: Safety of High-dose Nicotinamide... - Cure Parkinson's

Cure Parkinson's

25,541 members26,862 posts

NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease (NR-SAFE)

4 Replies

This trial was posted on April 25, 2022 by Haukeland University Hospital, the same sponsor for the NAD-PARK study.

Brief Summary:

NR-SAFE is a double-blinded randomized safety study aiming to determine the safety and tolerability of nicotinamide riboside (NR) at a daily dose of 3000mg, in individuals with Parkinson's disease (PD).

We recently reported the results of the NADPARK study (ClinicalTrials.gov: NCT03816020), a phase I randomized, double-blinded trial, assessing the tolerability, cerebral bioavailability and molecular effects of NR therapy, 1000mg daily, in PD. The NADPARK study showed that NR 1000mg daily was well tolerated and led to a significant, but variable, increase in cerebral NAD levels (measured by 31phosphorous magnetic resonance spectroscopy, 31P-MRS) and related metabolites in the cerebrospinal fluid (CSF). NR recipients showing increased brain NAD levels exhibited altered cerebral metabolism, measured by 18fluoro-deoxyglucose positron emission tomography (FDG-PET), and this was associated with mild clinical improvement. The results of the NADPARK trial nominate NR as a potential neuroprotective therapy for PD, warranting further investigation in larger trials.

It is plausible that any beneficial effects of NR in PD may be dose-dependent and more pronounced at higher doses. NR doses of up to 2000mg daily have been tested in healthy humans with no signs of toxicity. However, the safety and tolerability of even higher doses is untested. To enable clinical studies assessing higher doses, we will assess the safety and tolerability of an oral dose of 3000 mg NR daily.

NR-SAFE will recruit 20 participants with PD and randomize them 1:1 to either NR 3000mg daily or placebo for a total duration of 4 weeks.

clinicaltrials.gov/ct2/show...

Read more about...
4 Replies
jimcaster profile image
jimcaster

Wow. 3,000 mgs seems like a lot, although it's only for 30 days.

rescuema profile image
rescuema in reply to jimcaster

It is a lot. If they don't provide methylation support, many may end up dropping out.

healthunlocked.com/cure-par...

healthunlocked.com/cure-par...

You may also like...

Hot off the press. Randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson’s disease.

Abstract Nicotinamide adenine dinucleotide (NAD) replenishment therapy using nicotinamide riboside...

Encouraging results from the phase-I trial! The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in PD

We conducted a double-blinded phase I clinical trial to establish whether nicotinamide adenine...

Nicotinamide Riboside (TruNiagen brand)

newer members may not be familiar with Nicotinamide Riboside (Tru Niagen brand) as a means of...

Medium-Dose Lithium May Hit Parkinson Disease Targets...

people with Parkinson disease. The study randomized 5 patients to “high dose” lithium (lithium...

Nicotinamide Riboside supplement

I heard a quite bit about Nicotinamide Riboside recently that it helps with PD. When I look at...